Monthly Archives: February 2023

The therapeutic effect of immune checkpoint inhibitors (ICIs) is poor in hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) family members have important functions in immunity and oncology, but their roles in cancer im… Continue reading →

Alcohol disturbs hepatic lipid synthesis and transport, but the role of lipid dysfunction in alcohol-related liver disease (ALD) is unclear. In this biopsy-controlled, prospective, observational study, we characterized the liver and plasma lipidomes in… Continue reading →

Although small patient subsets benefit from current targeted strategies or immunotherapy, gemcitabine remains the first-line drug for pancreatic cancer (PC) treatment. However, gemcitabine resistance is widespread and compromises long-term survival. He… Continue reading →

There are emerging data revealing disparities in serious illness care for patients with advanced liver disease. Although liver disease is the 11th leading cause of death overall in adults in the United States, it is the 4th and 7th leading cause of dea… Continue reading →

Current colorectal cancer (CRC) screening recommendations take a one-size-fits-all approach using age as the major criterion to initiate screening. Precision screening that incorporates factors beyond age to risk stratify individuals could improve upon… Continue reading →